A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK® Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)

Trial Profile

A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK® Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 May 2018

At a glance

  • Drugs CVA 21 (Primary) ; Pembrolizumab (Primary)
  • Indications Bladder cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Solid tumours
  • Focus Therapeutic Use
  • Acronyms KEYNOTE-200; STORM
  • Sponsors Viralytics
  • Most Recent Events

    • 27 Feb 2018 Status changed from recruiting to active, no longer recruiting.
    • 13 Nov 2017 According to a Viralytics media release, results from this trial were presented at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
    • 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top